ΒιΆΉ΄«Γ½

Meeting Coverage

MHNCS

Multidisciplinary Head and Neck Cancer Symposium

Novel Therapy Promising for Radiation-Induced Oral Mucositis

No patient with head and neck cancer developed a severe case during 7 weeks of treatment

MHNCS over a photo of JW Marriott Desert Ridge Resort in Phoenix, AZ

Latest MHNCS Meeting Coverage

Gene-Guided Immunotherapy Misses Mark in Recurrent/Metastatic Head and Neck Cancer

Few responses with or without guidance in small first step for "personalized" treatment

March 4, 2024
Vismodegib-RT Regimen Achieves High Rate of Disease Control in Head and Neck BCC

Local control in 91% of cases at 1 year in small prospective trial

March 1, 2024
Two Pembrolizumab Trials in Head and Neck Cancer Yield Divergent Results

One first-line regimen led to worse OS, while another offers an additional option

March 1, 2024
Novel Therapies Active in Head and Neck Cancers

High response rate with oncolytic virus plus immunotherapy in cutaneous lesions

February 28, 2022
OncoBriefs: Zalutumumab Misses Mark in H&N Cancer

SCOTTSDALE, Ariz. -- Chemoradiation plus the targeted agent zalutumumab failed to improve disease control or survival in patients with squamous cell head and neck cancer, a finding that leads this roundup of news from the Multidisciplinary Head and Neck Cancer Symposium.

February 22, 2014
Oral Shield Cuts Radiation to Normal Tissue

PHOENIX -- Patients with head and neck cancer had substantial sparing of oral mucosa when they used custom-made dental stents to shield normal tissue from radiation therapy, data from a small clinical series showed.

January 31, 2012
Jaw Necrosis Common after Radiation for Oral Cancer

PHOENIX -- Osteoradionecrosis of the jaw occurred more than twice as often in patients treated for oral cancer as reported in the literature, according to a population-based study.

January 30, 2012